Clinical and economic consequences of switching from omalizumab to mepolizumab in uncontrolled severe eosinophilic asthma

Severe asthma is burdened by frequent exacerbations and use of oral corticosteroids (OCS), which worsen patients’ health and increase healthcare spending. The aim of this study was to assess the clinical and economic impact of switching from omalizumab (OMA) to mepolizumab (MEP) in patients eligible...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Sci Rep
Glavni autori: Carpagnano, Giovanna Elisiana, Resta, Emanuela, Povero, Massimiliano, Pelaia, Corrado, D’Amato, Mariella, Crimi, Nunzio, Scichilone, Nicola, Scioscia, Giulia, Resta, Onofrio, Calabrese, Cecilia, Pelaia, Girolamo, Barbaro, Maria Pia Foschino
Format: Artigo
Jezik:Inglês
Izdano: Nature Publishing Group UK 2021
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7943587/
https://ncbi.nlm.nih.gov/pubmed/33750842
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-021-84895-2
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items